Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to -$7.8 million.

  • Lifecore Biomedical's Gains from Investment Securities fell 7181.15% to -$8.9 million in Q2 2025 from the same period last year, while for May 2025 it was -$7.8 million, marking a year-over-year decrease of 325.38%. This contributed to the annual value of -$7.8 million for FY2025, which is 325.38% down from last year.
  • Latest data reveals that Lifecore Biomedical reported Gains from Investment Securities of -$7.8 million as of FY2025, which was down 325.38% from -$1.8 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Gains from Investment Securities ranged from a high of $789,000 in FY2022 and a low of -$7.8 million during FY2025.
  • For the 3-year period, Lifecore Biomedical's Gains from Investment Securities averaged around -$3.1 million, with its median value being -$1.8 million (2024).
  • Per our database at Business Quant, Lifecore Biomedical's Gains from Investment Securities skyrocketed by 110.27% in 2022 and then tumbled by 767.15% in 2024.
  • Yearly analysis of 5 years shows Lifecore Biomedical's Gains from Investment Securities stood at -$7.7 million in 2021, then skyrocketed by 110.27% to $789,000 in 2022, then tumbled by 65.27% to $274,000 in 2023, then crashed by 767.15% to -$1.8 million in 2024, then tumbled by 325.38% to -$7.8 million in 2025.